Rani Therapeutics Holdings, Inc. (RANI)
Fuera de horario:
Rani Therapeutics Holdings, Inc.
2051 Ringwood Avenue
San Jose, CA 95131
United States
408 457 3700
https://www.ranitherapeutics.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 140
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Mir A. Imran | Executive Chairman | 80k | N/D | 1957 |
| Mr. Talat Imran | CEO & Director | 450k | N/D | 1982 |
| Mr. Svai S. Sanford | Chief Financial Officer | 416k | N/D | 1970 |
| Dr. Mir Hashim | Chief Scientific Officer | 416k | N/D | 1960 |
| Mr. Eric Groen | General Counsel | N/D | N/D | 1971 |
| Ms. Bella Vazquez | Vice President of Human Resources | N/D | N/D | N/D |
| Ms. Kate McKinley M.B.A. | Chief Business Officer | N/D | N/D | 1977 |
| Ms. Arvinder Dhalla | Vice President of Clinical Development | N/D | N/D | N/D |
Descripción
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
Gestión corporativa
La calificación ISS Governance QuickScore de Rani Therapeutics Holdings, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
